Related Experiment Videos
[F-18 fluorodeoxyglucose for diagnosis of myocardial viability: applications in clinical practice]
1Klinische Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Währinger Gürtel 18-20, A-1090 Wien. senta.graf@akh-wien.ac.at
Insights
Assessing myocardial viability is crucial for managing ischemic cardiomyopathy. Cardiac F-18-fluorodeoxyglucose-positron emission tomography (F-18-FDG-PET) is the gold standard for detecting viable heart muscle, guiding treatment decisions.
Area of Science:
- Cardiology
- Nuclear Medicine
- Medical Imaging
Background:
- Ischemic cardiomyopathy, heart failure from chronic ischemic heart disease, is rising.
- Left ventricular dysfunction post-ischemia may be reversible (hibernating/stunned myocardium).
- Identifying viable myocardium is key for therapeutic stratification.
Purpose of the Study:
- To review cardiac F-18-fluorodeoxyglucose-positron emission tomography (F-18-FDG-PET) for myocardial viability assessment.
- To highlight F-18-FDG-PET's role in clinical decision support for ischemic cardiomyopathy.
- To discuss predicting left ventricular function improvement after revascularization.
Main Methods:
- Cardiac F-18-FDG-PET imaging is the focus.
- Review of clinical applications and interpretation of F-18-FDG-PET.
- Discussion of F-18-FDG-PET as the gold standard for viability.
Main Results:
- F-18-FDG-PET is highly effective in assessing myocardial viability.
- Viability assessment guides revascularization decisions.
- Predicts functional recovery of the left ventricle.
Conclusions:
- F-18-FDG-PET is essential for managing patients with ischemic cardiomyopathy.
- It provides critical information for treatment planning and predicting outcomes.
- This review covers the clinical utility of F-18-FDG-PET imaging.
Abstract:
The number of patients with heart failure secondary to chronic ischemic heart disease, also called ischemic cardiomyopathy, is increasing in clinical cardiology. Left ventricular dysfunction after ischemic episodes has been shown to be potentially reversible, as in the case of hibernating or stunned myocardium. Thus, the detection of viable myocardium is of critical importance for a therapeutic stratification of patients with left ventricular dysfunction. Viability assessment should prove decision support to achieve an optimal management of patients with ischemic cardiomyopathy by predicting the capacity of improvement of left ventricular function after revascularisation. Cardiac F-18-fluorodeoxyglucose-positron emission tomography (F-18-FDG-PET) imaging is considered the "gold-standard" for assessment of myocardial viability. This article reviews the fluorodeoxyglucose-positron emission tomography imaging from a clinical viewpoint.